Why the study?
Does a four-hour infusion of Cenderitide increase cGMP levels safely in subjects with stable chronic heart failure?
Does a four-hour infusion of Cenderitide increase cGMP levels safely in subjects with stable chronic heart failure?
Cenderitide, a novel designer natriuretic peptide, safely increases cGMP levels without causing hypotension in patients with stable heart failure, supporting its further clinical development.
No takes yet. Share an insight, caveat, or question.
Supports Cenderitide advancement in stable HF; extends rationale for designer natriuretic peptides.
Kawakami et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: